



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.



Available online at
ScienceDirect
www.sciencedirect.com

Elsevier Masson France
EM|consulte
www.em-consulte.com/en



RESEARCH LETTER

COVID-19 vaccines and myocarditis



Vaccins COVID-19 et myocardite

Keywords Myocarditis; COVID-19; Vaccines; Pharmacovigilance
Mots clés Vaccin ; COVID-19 ; Myocardite ; Pharmacovigilance

In May 2021, concerns about possible cases of myocarditis following coronavirus disease 2019 (COVID-19) vaccination were raised by the European Medicines Agency safety committee [1].

We analysed reporting of myocarditis (myocarditis preferred term level using the Medical Dictionary for Regulatory Activities) associated with vaccines (J07 using the Anatomical Therapeutic Chemical Classification System) versus all other drugs, worldwide, from inception (1967) to 7 May 2021, in the international pharmacovigilance database Vigibase. We used the information component (IC), an indicator value for disproportionate Bayesian reporting comparing observed and expected values to find signals for associations between drugs and adverse events [2]. $IC_{0.25}$ is the lower end of the IC 95% credibility interval. A positive $IC_{0.25}$ is deemed significant. We used clozapine and atorvastatin as positive and negative controls, respectively. Individual case reviews of each report of suspected COVID-19 vaccine-related myocarditis were then performed. Suspected myocarditis was classified according to the consensus definition of drug-induced autoimmune myocarditis as possible, probable or definite, based on the presence or absence of compatible clinical symptoms, electrocardiogram, abnormal troponin concentrations, cardiac magnetic resonance imaging, endomyocardial biopsy results or exclusion of coronary artery disease, when available [3].

Vigibase contained a total of 25,728,751 adverse drug reaction reports, including 8664 reports of myocarditis, of which 1251 involved a suspected culprit vaccine. Among these latter reports, 214 (17.1%) were associated with

COVID-19 vaccines. Only messenger ribonucleic acid (mRNA) COVID-19 vaccines, including mRNA1273 (Moderna®, $n = 51$, $IC_{0.25} = 1.1$) and tozinameran (Pfizer/BioNTech®, $n = 105$, $IC_{0.25} = 0.05$) were significantly associated with myocarditis, whereas other types of COVID-19 vaccine were not (Fig. 1). The magnitude of the associations with liable non-COVID-19 vaccines and positive and negative controls are also shown in Fig. 1.

The median age of patients with COVID-19 vaccine-related myocarditis was 35 years (interquartile range 25–50 years) and 131/205 (63.9%) were male; five patients died. Disproportional association as a function of age and sex group showed over-reporting in males for the mRNA1273 and tozinameran vaccines, and in younger people for the mRNA1273 vaccine (Fig. 1). Of importance, 188/214 (88%) patients were free from any other reported medication. No case of concurrent eosinophilia was reported. Associated pericarditis was reported in 47/214 (22%) cases. The median time to onset between last dose of vaccine received and the adverse event was 3 days (interquartile range 1–6 days; n available = 202). Notably, sufficient data were available to classify 23 cases as definite, 16 as probable and 46 as possible myocarditis. No patient with definite myocarditis died.

Vaccines are a known, but rare, cause of myocarditis, considering the population exposed [4]. Despite the inherent limitation of such an analysis, this report suggests that, similar to other vaccines, mRNA COVID-19 vaccines are associated with myocarditis. We acknowledge several sources of bias caused by the nature of the pharmacovigilance database, including underreporting, associated with halo bias and a lack of detailed information on the exposed population for calculation of incidence. However, given that approximately half a billion patients have received at least one dose of a COVID-19 vaccine at the time of this analysis, we strongly believe that these results do not change the clear and favourable balance of benefit over risk for COVID-19 vaccines. Nevertheless, physicians should be aware of this rare but potentially life-threatening adverse event, with early recognition being critical to provide appropriate care [5].




Figure 1. Information component (IC) and its 95% credibility interval lower endpoint (IC₀₂₅) comparing myocarditis associated with vaccines (J07 using the Anatomical Therapeutic Chemical Classification System) versus the full VigiBase database (until 05 July 2021). A positive IC₀₂₅ value (> 0) is the traditional threshold used in statistical signal detection with VigiBase. A. Coronavirus disease 2019 (COVID-19) vaccines and non-COVID-19 vaccines significantly associated with myocarditis are in black (bold) and grey, respectively; COVID-19 vaccines non-significantly associated with myocarditis are in black (non-bold). B. Subgroup analysis of IC as a function of sex and age for COVID-19 liable vaccines. mRNA: messenger ribonucleic acid; N_{drug}: the number of reports for the drug, regardless of the adverse drug reaction; N_{obs}: the actual number of reports observed for the drug-adverse drug reaction combination; v.: vaccine.

Sources of funding

None.

Acknowledgements

The supplied data came from a variety of sources. The likelihood of a causal relationship was not the same in all reports. The information does not represent the opinion of the World Health Organization.

Disclosure of interest

M.K. Consulting fees from the companies Sanofi, Bayer and Kiniksa. Research grants from the Federation Française de Cardiologie and the French Health Ministry.

J.-E.S. Consulting fees from the company BMS. Research grants from the companies BMS and Novartis, and from the Federation Française de Cardiologie, the Société Française de Cardiologie, INSERM and the Agence Nationale de la Recherche.

K.B. declares that he has no competing interest.

References

- [1] EMA. Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 3–6 May 2021; 2021 <https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-3-6-may-2021>.
- [2] Salem JE, Manouchehri A, Moey M, et al. Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study. *Lancet Oncol* 2018;19:1579–89.
- [3] Bonaca MP, Olenchock BA, Salem JE, et al. Myocarditis in the Setting of Cancer Therapeutics: Proposed Case Definitions for Emerging Clinical Syndromes in Cardio-Oncology. *Circulation* 2019;140:80–91.
- [4] Engler RJ, Nelson MR, Collins Jr LC, et al. A prospective study of the incidence of myocarditis/pericarditis and new onset cardiac symptoms following smallpox and influenza vaccination. *PLoS One* 2015;10:e0118283.
- [5] Kociol RD, Cooper LT, Fang JC, et al. Recognition and Initial Management of Fulminant Myocarditis: A Scientific Statement From the American Heart Association. *Circulation* 2020;141:e69–92.

Mathieu Kerneis^{a,*}, Kevin Bihan^b,
Joe-Elie Salem^b

^a Sorbonne Université, ACTION Study Group,
INSERM UMRS1166, ICAN—Institute of
CardioMetabolism and Nutrition, Institut de
Cardiologie, Hôpital Universitaire

Pitié-Salpêtrière, AP–HP, 75013 Paris, France
^b Sorbonne Université, Clinical Investigations
Center Paris-Est, Hôpital Universitaire
Pitié-Salpêtrière, AP–HP, INSERM, 75013 Paris,
France

* Corresponding author.

E-mail address: mathieu.kerneis@aphp.fr
(M. Kerneis)

Received 9 June 2021;

received in revised form 16 June 2021;

accepted 21 June 2021

Available online 26 June 2021

<https://doi.org/10.1016/j.acvd.2021.06.001>

1875-2136/© 2021 Elsevier Masson SAS. All rights reserved.